Belgium: ArchiMed takes majority stake in Xpress Biologics and adds to Board

French healthcare specialist investor, ArchiMed, has acquired a majority stake in Xpress Biologics. The Belgium-based Contract Service Organisation (CSO) is a developer of expression systems and manufacturing processes for the production of plasmid DNA and protein therapeutics. The investment is planned to finance a 10-fold Good Manufacturing Practices (GMP) capacity expansion. As part of the transaction,…

You must be a HMI Subscriber to view this content.

Subscribe Now »